共 208 条
[1]
Furqan M(2013)Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application Biomark Res 1 5-36
[2]
Mukhi N(2016)Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases Nat Rev Rheumatol 12 25-2613
[3]
Lee B(2013)JAK/STAT signaling in hematological malignancies Oncogene 32 2601-314
[4]
Liu D(2018)JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders F1000Res 7 82-906
[5]
Schwartz DM(2020)Excretion balance and pharmacokinetics following a single oral dose of [(14)C]-fedratinib in healthy subjects Cancer Chemother Pharmacol 86 307-850
[6]
Bonelli M(2020)Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects Cancer Chemother Pharmacol 85 899-1148
[7]
Gadina M(2003)Pharmacokinetic interactions with rifampicin: clinical relevance Clin Pharmacokinet 42 819-242
[8]
O'Shea JJ(2011)Simulation of clinical drug–drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs Drug Metab Dispos 39 1139-9
[9]
Vainchenker W(2011)Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug–drug interaction trial design Clin Pharmacol Ther 89 234-1001
[10]
Constantinescu SN(2002)Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans Clin Pharmacol Ther 72 1-898